A maintenance medication after cellular therapy for high-risk lymphoma

Plain-English translation of NCT05256641 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a medication called given as a maintenance treatment after you receive cellular therapy (like CAR T-cell therapy or stem cell transplant) for aggressive B-cell lymphoma. The goal is to see whether taking this medication for one year after your initial treatment can help prevent your lymphoma from coming back and keep you in remission longer.

Patients with high-grade or transformed B-cell lymphomas have a very high risk of their cancer returning even after receiving cellular therapy. Researchers want to find out whether adding this maintenance treatment can improve outcomes and give patients a better chance at long-term remission.

Do you qualify?

You likely qualify if…

you are 18–70 years old
you have been diagnosed with an aggressive B-cell lymphoma (such as high-grade lymphoma, lymphoma that transformed from a slower-growing type, or lymphoma with previous brain involvement)
you have had a partial or complete response to your stem cell transplant or CAR T-cell therapy
you are able to swallow pills without difficulty
you have adequate blood counts, liver, and kidney function at the time of enrollment

You likely don't qualify if…

you have had a severe allergic reaction to similar medications
you have very severe heart disease or severely reduced heart function
you have severe kidney disease or are taking certain antifungal medications that cannot be stopped
you have severe graft-versus-host disease after transplant
you have an active, uncontrolled infection

What participation looks like

If you enroll, you will take the medication by mouth once or twice daily for one year, starting sometime between 28 and 104 days after your cellular therapy (depending on which group you are assigned to). You will visit the clinic regularly for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and to watch for any side effects. The trial will track whether your cancer stays in remission and how long the benefit lasts.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Trial locations(3 sites)

United States

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

University of Oklahoma, Oklahoma City, Oklahoma